Please assess the completion status of the following clinical trial:

Trial Title: Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III to V Chronic Kidney Disease~* Serum Phosphorus 4.0-6.0 mg/dL prior to Randomization~* Ferritin 300 ng/mL or less~* Transferrin Saturation (TSAT) 30% or less~* Hemoglobin \>9.0 and \<12.0 g/dL~* Must consume a minimum of 2 meals per day~Exclusion Criteria:~* Parathyroidectomy within 24 weeks of study~* gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study~* Requirement for dialysis or kidney injury within 8 weeks of study~* Absolute requirement for oral iron, intravenous iron, Erythropoiesis-Stimulating Agent, blood transfusions, and Sensipar during the study~* Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals~* Absolute requirement for vitamin C, niacin, or nicotinamide outside of multivitamins~* History of hemochromatosis~* Allergy to iron products~* History of malignancy in last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Citrate (Type: EXPERIMENTAL): Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).